Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William R Wilson

Showing results (41-50 of 125) with videos related to

Pageof 13
Sort By:
Pharmaceutical Research|March 1, 2022
Calcium Enabled Remote Loading of a Weak Acid Into pH-sensitive Liposomes and Augmented Cytosolic Delivery to Cancer Cells via the Proton Sponge EffectMimi M Yang, Sasi Bhushan Yarragudi, Stephen M F Jamieson, et al.
Methods in Molecular Medicine|December 6, 2003
In vitro and in vivo models for evaluation of GDEPT: quantifying bystander killing in cell cultures and tumorsWilliam R Wilson, Susan M Pullen, Alison Hogg, et al.
Biochemical Pharmacology|July 25, 2007
Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxiaChris P Guise, Anderson T Wang, Anke Theil, et al.
Cancer Research|March 13, 2002
Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell culturesWilliam R Wilson, Susan M Pullen, Alison Hogg, et al.
Biochemical Pharmacology|April 20, 2006
Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylatorG-One Ahn, K Jane Botting, Adam V Patterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2011
The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxiaJingli Wang, Annika Foehrenbacher, Jiechuang Su, et al.
Frontiers in Pharmacology|October 4, 2018
Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell CulturesCho R Hong, Gib Bogle, Jingli Wang, et al.
Dalton Transactions (Cambridge, England : 2003)|July 15, 2004
Anionic carbonato and oxalato cobalt(III) nitrogen mustard complexesPeter R Craig, Penelope J Brothers, George R Clark, et al.
Cancer Gene Therapy|September 8, 2023
Clonal dynamics limits detection of selection in tumour xenograft CRISPR/Cas9 screensTet Woo Lee, Francis W Hunter, Peter Tsai, et al.
Cancer Chemotherapy and Pharmacology|December 17, 2009
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumorsMichael B Jameson, Danny Rischin, Mark Pegram, et al.
Pageof 13

Showing results (41-50 of 125) with videos related to

Sort By:
Pageof 13
Pharmaceutical Research|March 1, 2022
Calcium Enabled Remote Loading of a Weak Acid Into pH-sensitive Liposomes and Augmented Cytosolic Delivery to Cancer Cells via the Proton Sponge EffectMimi M Yang, Sasi Bhushan Yarragudi, Stephen M F Jamieson, et al.
Methods in Molecular Medicine|December 6, 2003
In vitro and in vivo models for evaluation of GDEPT: quantifying bystander killing in cell cultures and tumorsWilliam R Wilson, Susan M Pullen, Alison Hogg, et al.
Biochemical Pharmacology|July 25, 2007
Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxiaChris P Guise, Anderson T Wang, Anke Theil, et al.
Cancer Research|March 13, 2002
Quantitation of bystander effects in nitroreductase suicide gene therapy using three-dimensional cell culturesWilliam R Wilson, Susan M Pullen, Alison Hogg, et al.
Biochemical Pharmacology|April 20, 2006
Radiolytic and cellular reduction of a novel hypoxia-activated cobalt(III) prodrug of a chloromethylbenzindoline DNA minor groove alkylatorG-One Ahn, K Jane Botting, Adam V Patterson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2011
The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxiaJingli Wang, Annika Foehrenbacher, Jiechuang Su, et al.
Frontiers in Pharmacology|October 4, 2018
Bystander Effects of Hypoxia-Activated Prodrugs: Agent-Based Modeling Using Three Dimensional Cell CulturesCho R Hong, Gib Bogle, Jingli Wang, et al.
Dalton Transactions (Cambridge, England : 2003)|July 15, 2004
Anionic carbonato and oxalato cobalt(III) nitrogen mustard complexesPeter R Craig, Penelope J Brothers, George R Clark, et al.
Cancer Gene Therapy|September 8, 2023
Clonal dynamics limits detection of selection in tumour xenograft CRISPR/Cas9 screensTet Woo Lee, Francis W Hunter, Peter Tsai, et al.
Cancer Chemotherapy and Pharmacology|December 17, 2009
A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumorsMichael B Jameson, Danny Rischin, Mark Pegram, et al.
Pageof 13